本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 三诺生物传感股份有限公司（以下简称"公司"）第五届监事会第十二次会 议于 2025 年 2 月 20 日（星期四）下午 15 时在公司会议室以现场方式召开。本 次会议的通知已于 2025 年 2 月 18 日通过书面或电子邮件方式送达全体监事。应 出席本次会议的监事 3 人，实际出席本次会议的监事 3 人，分别为欧阳柏伸先 生、陈春耕先生和黄绍波先生，会议由监事会主席欧阳柏伸先生召集并主持，公 司董事会秘书郑霁耘女士（兼任副总经理）列席了会议。会议的召集、召开符合 《公司法》及《公司章程》《公司监事会议事规则》的规定。 | 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-009 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 第五届监事会第十二次会议决议公告 二、会议审议情况 （一）逐项审议并通过《关于回购公司部分股份方案的议案》 1、回购股份的目的 基于对公司未来发展前景的信心和对公司长期 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-007 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于回购公司部分股份方案暨取得金融机构股票回购 专项贷款承诺函的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 三诺生物传感股份有限公司 1、三诺生物传感股份有限公司（以下简称"公司"或"上市公司"）拟使 用自有资金及银行回购专项贷款以集中竞价交易的方式回购公司部分社会公众 股份： （1）拟回购股份的种类：公司发行的人民币普通股（A 股）股票。 （2）拟回购股份的用途：本次回购股份用于员工持股计划、股权激励或者 用于转换上市公司发行的可转换为股票的公司债券。 （3）拟回购股份的价格区间：不超过人民币 34.00 元/股（含）。 （4）拟用于回购的资金总额：回购资金总额不低于人民币 15,000 万元且不 超过人民币 30,000 万元（均含本数）。 （5）拟回购股份的数量和占总股本的比例：按回购资金总额上限人民币 30,000 ...

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company's continuous glucose monitoring (CGM) products are successfully expanding into European and American markets, which is expected to open a second growth curve. The approval of the second-generation CGM will enhance product competitiveness [4] - The partnership with A. MENARINI DIAGNOSTICS S.r.l. for exclusive distribution in over 20 European countries is anticipated to significantly accelerate market penetration and coverage of CGM products [1] - The CGM market in the U.S. is projected to grow, with the company leveraging its subsidiaries Trividia and PTS to enhance sales channels upon FDA approval [2] - The newly approved second-generation CGM product in China offers improved comfort and convenience, which is expected to enhance user experience and product competitiveness [3] Summary by Sections Company Overview - The company has established a seven-year distribution agreement with A. MENARINI DIAGNOSTICS S.r.l. to promote CGM products in Europe, which is the second-largest market for CGM [1] - The U.S. CGM market was valued at $2.7 billion in 2020, with a compound annual growth rate (CAGR) of 26.7% from 2015 to 2020 [2] Product Development - The second-generation CGM product has received regulatory approval in China, featuring a more user-friendly design that enhances portability and comfort [3] Financial Forecast - Revenue projections for 2024-2026 have been revised upwards to 43.33 billion, 49.00 billion, and 56.49 billion yuan respectively, with net profits adjusted to 3.64 billion, 4.67 billion, and 5.94 billion yuan [4] - The earnings per share (EPS) estimates for the same period are 0.61, 0.78, and 1.03 yuan [4] Market Position - The company is positioned to benefit from the growing CGM market in both Europe and the U.S., with strategic partnerships and product innovations enhancing its competitive edge [1][2][3]

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-006 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 | 获得补助的 | 收到补助的时间 | | 补助 | 补助金额 | 是否与公司 日常经营活 | 是否已经 实际收到 | 是否具有 | | --- | --- | --- | --- | --- | --- | --- | --- | | 主体 | | | 形式 （元） | | | | 可持续性 | | | | | | | 动相关 | 款项 | | | 三诺生物 | 2025 年 1 月 23 日 | 现金 | | 29,615,015.44 | 是 | 是 | 是 | 二、补助的类型及其对上市公司的影响 1、补助的类型 根据《企业会计准则第 16 号——政府补助》的规定，与资产相关的政府补 助，是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与收益 相关的政府补助，是 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-004 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 二、会议审议情况 本次会议采用现场和通讯表决方式进行表决，经与会董事认真审议，本次会 议形成以下决议： （一）审议并通过《关于制定公司〈舆情管理制度〉的议案》 为提高公司应对各类舆情的能力，建立快速反应和应急处置机制，及时、妥 善处理各类舆情对公司商业信誉、正常生产经营活动以及投资价值等造成的影响， 切实保护公司及利益相关方合法权益，经与会董事审议，一致同意公司根据相关 法律法规、规范性文件和《公司章程》的有关规定，并结合公司实际情况，制定 《舆情管理制度》。 具体内容详见公司同日在中国证监会指定的创业板信息披露网站（巨潮资讯 网 www.cninfo.com.cn）上披露的《舆情管理制度》。 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 三诺生物传感股份有限公司（以下简称"公司"）第五届董事会第 ...

三诺生物传感股份有限公司 三诺生物传感股份有限公司 舆情管理制度 （2025 年 1 月） 第一章 总则 第一条 为提高三诺生物传感股份有限公司（以下简称"公司"）应对各类舆 情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司商业 信誉、正常生产经营活动以及投资价值等造成的影响，切实保护公司及利益相关 方合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证 券交易所创业板股票上市规则》等法律法规、规范性文件和《三诺生物传感股份 有限公司章程》（以下简称"《公司章程》"）的有关规定，结合公司实际情况， 特制定本管理制度。 第二条 本管理制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道、不实报道； （二）社会上存在的已经或者将给公司造成不良影响的传言或信息； （三）可能或者已经影响公众投资者投资取向，造成股价异常波动的信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第三条 公司应对各类舆情遵循"统一领导、统一组织、快速反应、协同应 对"基本原则，有效把握、引导舆论导向，避免和消除因媒体报道可能对公司造 成的各种负 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-001 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 1、三诺转债（债券代码：123090）转股期为2021年6月25日至2026年12月20 日；转股价格为人民币34.61元/股。 2、2024年第四季度，共有0张"三诺转债"完成转股（票面金额共计0元人 民币），合计转成0股"三诺生物"股票（股票代码：300298）。 3、截至2024年第四季度末，公司剩余可转债为4,984,224张，剩余可转债票 面总金额为498,422,400元人民币。 根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司 自律监管指引第15号——可转换公司债券》的有关规定，三诺生物传感股份有限 公司（以下简称"公司"或"三诺生物"）现将2024年第四季度可转换公司债券 （以下简称"可转债"）转股及公司股份变动情况公告如下： 关于2024年第四季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重 ...

Investment Rating - Buy (Maintained Rating) [8][15] Core Views - The company's second-generation CGM (Continuous Glucose Monitoring) product has been approved domestically and is under FDA review, with catalysts both domestically and internationally expected to drive growth [5] - The second-generation CGM product features improved performance and user experience, utilizing third-generation direct electron transfer technology, which offers advantages such as low potential, oxygen independence, fewer interferences, better stability, and higher accuracy [5] - The product is designed for integration with Automated Insulin Delivery (AID) systems and targets the US market, which is the largest CGM market globally, with significant growth potential post-registration [4][14] - The company has secured a 7-year distribution agreement with a major European distributor, and both semi-automated and fully automated production lines are operational, positioning the company to capitalize on the global CGM market [6] Financial Performance and Projections - Revenue is projected to grow from 4,059 million RMB in 2023 to 5,928 million RMB in 2026, with a CAGR of 19% [7][10] - Net profit attributable to the parent company is expected to increase from 284 million RMB in 2023 to 635 million RMB in 2026, with a CAGR of 24% [7][10] - EPS is forecasted to rise from 0.50 RMB in 2023 to 1.13 RMB in 2026 [7][10] - The company's gross margin is expected to remain stable at around 54%, with net profit margin improving from 4.8% in 2023 to 11.0% in 2026 [10] Market and Industry Insights - The US CGM market is projected to grow from 2.7 billion USD in 2020 to 15.4 billion USD in 2030, with a CAGR of 19% [4] - The European CGM market is expected to expand from 1.2 billion USD in 2020 to 7.8 billion USD in 2030 [4] - The company's CGM product has received regulatory approval in China and is under FDA review in the US, with significant commercialization potential in the US market [13][14] Operational and Strategic Developments - The company has received regulatory approval for its CGM system in China, including an 8-day version for medical institutions and a 15-day version for home use [13] - The FDA has accepted the company's CGM product for substantive review, marking a key milestone in its US market entry [13] - The company has established both semi-automated and fully automated production lines, enhancing its capacity to meet global demand [6]

三诺生物传感股份有限公司（以下简称"公司"或"三诺生物"）于近日收 到湖南省药品监督管理局颁发的一项《中华人民共和国医疗器械注册证》，现将 具体情况公告如下： | 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2024-090 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 二〇二四年十二月二十六日 | 序 | 产品名称 | 注册证编号 | 注册证 | 注册 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 号 | | | 有效期 | 分类 | | | 1 | 血糖尿酸血脂仪 | 湘械注准 20242221261 | 2024.12.09 | | 本产品与配套试条配合使用，用于定量检测 | | | | | | | 新鲜毛细血管全血、静脉全血和动脉全血中 | | | | | | | 的葡萄糖浓度，新鲜毛细血管全血、静脉全 | | | | | ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company has achieved significant milestones in its overseas market expansion, particularly with its Continuous Glucose Monitoring (CGM) system, which has received FDA acceptance and NMPA approval for various models [1][2] - The CGM product line is expected to see substantial sales growth, with projected revenues of 300 to 500 million yuan in 2024, following an estimated 80 million yuan in sales for 2023 [2] - The company has signed a distribution agreement with A.MENARINI DIAGNOSTICS S.r.l. for exclusive distribution in over 20 European countries, indicating strong international market penetration [1][3] Summary by Sections Product Development and Approval - The company’s CGM products have received necessary approvals, including FDA 510(k) acceptance and NMPA approval, with five models categorized for home and medical use [1] - The new generation of CGM products reflects the company's commitment to innovation and expanding its diabetes monitoring product line [2] Sales and Revenue Projections - The company anticipates a sales target of 300 to 500 million yuan for its CGM products in 2024, with profitability expected by 2025 [2] - The CGM industry is projected to experience accelerated growth, benefiting from the company's long-term investment in sensor technology since 2008 [2] International Expansion - The company has received CE certification for its CGM products and is poised for significant market penetration in Europe, with clinical trials in the U.S. progressing well [3] - The operational performance of overseas subsidiaries is improving, with expectations of profitability in the near term [3]